Treatment of Obesity for Primary Care: From Diagnosis to Care Management-Diabesity

Video Transcription

Video Summary

In this video transcript, Dr. Karla San André discusses the relationship between diabetes and obesity. Diabetes affects 11.3% of the US population and 10.5% of the global population, while prediabetes affects 40% and 5.8% respectively. Obesity contributes to 80-90% of type 2 diabetes cases, and 90% of type 2 diabetes patients have obesity. Weight gain increases the risk of developing diabetes, while weight loss decreases the risk. Dr. San André discusses the evidence for treating obesity to manage diabetes and cardiovascular risks. Weight loss has been associated with improved glycemic control, lipid profile, blood pressure, reduced risk of cardiovascular events, and positive impact on inflammatory markers. GLP-1 receptor agonists, such as semaglutide, have shown efficacy in weight loss and glucose regulation. Bariatric surgery has also been found to reduce the incidence of diabetes in people with obesity. The ACE clinical practice guidelines recommend lifestyle therapy, weight loss medications, and bariatric surgery for managing diabetes and obesity. GLP-1 receptor agonists have shown a reduction in major adverse cardiovascular events. The use of trisepatide has also shown promising results in weight loss and reducing cardiovascular risk factors.

Keywords

diabetes

obesity

weight loss

GLP-1 receptor agonists

bariatric surgery

cardiovascular risk factors